A phase II study evaluating the toxicity and efficacy of single-agent temsirolimus in chemotherapy-naïve castration-resistant prostate cancer
K Kruczek, M Ratterman, K Tolzien, S Sulo… - British journal of …, 2013 - nature.com
Background: The mammalian target of rapamycin (mTOR) pathway is deregulated in
castration-resistant prostate cancer (CRPC). We investigated the efficacy and toxicity of …
castration-resistant prostate cancer (CRPC). We investigated the efficacy and toxicity of …
Lenalidomide monotherapy in chemotherapy-naive, castration-resistant prostate cancer patients: final results of a phase II study
Background We investigated the activity of lenalidomide, which has antiangiogenic,
antineoplastic, and immunomodulatory properties, in chemotherapy-naive, castration …
antineoplastic, and immunomodulatory properties, in chemotherapy-naive, castration …
Role of sorafenib in overcoming resistance of chemotherapy-failure castration-resistant prostate cancer
A Meyer, P Cygan, K Tolzien, AG Galvez… - Clinical genitourinary …, 2014 - Elsevier
Background Sorafenib promotes apoptosis through downstream pathways that can be
deregulated in CRPC. We hypothesized that sorafenib could overcome chemotherapy …
deregulated in CRPC. We hypothesized that sorafenib could overcome chemotherapy …
Pretreatment metabolic parameters measured by 18F-FDG-PET to predict the outcome of first-line chemotherapy in extensive-stage small-cell lung cancer
X Yu, Y Zhu, J Wang, X Song, L Zhu… - Nuclear Medicine …, 2017 - journals.lww.com
Objective Patients' pretreatment metabolic burden, as measured by radiotracer fluorine-18
fluorodeoxyglucose (18 F-FDG) PET/computed tomography (CT), has been shown to predict …
fluorodeoxyglucose (18 F-FDG) PET/computed tomography (CT), has been shown to predict …
Gemcitabine and cisplatin salvage regimen in heavily pretreated metastatic breast cancer: a Brazilian experience
LH de Lima Araújo, MV Moitinho, AMF Silva… - Medical Oncology, 2011 - Springer
Gemcitabine and cisplatin combination (Gem–Cis) is a commonly used regimen in
metastatic breast cancer (MBC), with proven activity in phase II trials. It is mostly used as a …
metastatic breast cancer (MBC), with proven activity in phase II trials. It is mostly used as a …
[PDF][PDF] Pemetreksed (Alimta®) w I linii leczenia pacjentów z niedrobnokomórkowym rakiem płuca
AOT Medycznych, WOT Medycznych - wwwold.aotm.gov.pl
Po zapoznaniu się z przedstawionym konfliktem interesów, decyzją Dyrektora OT opinia
następujących ekspertów została dopuszczona do procesu oceny przedmiotowego …
następujących ekspertów została dopuszczona do procesu oceny przedmiotowego …
[PDF][PDF] Pemetreksed (Alimta®) w II linii leczenia niedrobnokomórkowego raka płuca
AOT Medycznych, WOT Medycznych - wwwold.aotm.gov.pl
PFS (progression-free survival)–czas wolny od progresji QL (quality of life)–jakość życia
SDR (stable disease rate)–stabilizacja choroby SG3/4 (survival without grade 3/4 toxicity or …
SDR (stable disease rate)–stabilizacja choroby SG3/4 (survival without grade 3/4 toxicity or …
[PDF][PDF] Comparação entre pemetrexede e cisplatina versus pemetrexede e carboplatina no tratamento de primeira linha de carcinoma de pulmão de células não …
ATAR Pereira, RC Lessa, CEP de Souza… - Revista Brasileira de …, 2010 - sboc.org.br
OBJETIVOS: Comparar a eficácia de pemetrexede e cisplatina (PC) versus pemetrexede e
carboplatina (PCar) no tratamento de carcinoma de pulmão de células não-pequenas …
carboplatina (PCar) no tratamento de carcinoma de pulmão de células não-pequenas …